AR047325A1 - Derivados de indano sustituidos y compuestos relacionados para el tratamiento de la esquizofrenia. composiciones farmaceuticas que los contienen. - Google Patents
Derivados de indano sustituidos y compuestos relacionados para el tratamiento de la esquizofrenia. composiciones farmaceuticas que los contienen.Info
- Publication number
- AR047325A1 AR047325A1 ARP040104547A ARP040104547A AR047325A1 AR 047325 A1 AR047325 A1 AR 047325A1 AR P040104547 A ARP040104547 A AR P040104547A AR P040104547 A ARP040104547 A AR P040104547A AR 047325 A1 AR047325 A1 AR 047325A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- fluorine atoms
- integer
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 240000001546 Byrsonima crassifolia Species 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000001153 fluoro group Chemical group F* 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- -1 -SO2-aryl Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de grupo de formulas (1), en el que J es S, SO, SO, CH2, O o NR10, en el que R10 es hidrogeno, alquilo C1-6, C(=O)alquilo(C1-6) o C(=O)O-alquilo(C1-6); M es CH o N; G es CH o N; m es un numero entero de uno a seis; X es O o NR3, en el que R3 se define tal como se define R10 anteriormente, C(=O), CHOH, CHOR3, CH(halo) o CHNR3R12, en el que R12 se define tal como se define R10 anteriormente; o X está ausente; R1 es hidrogeno, halogeno, ciano, alquilo C1-6 opcionalmente sustituido con uno a tres átomos de fluor o R1 forma un anillo heterocíclico con R10; R2 se define tal como R1 con la condicion de que R2 no puede formar un anillo heterocíclico cuando está presente R1; R4 y R5 son, independientemente, hidrogeno, halogeno, ciano, aminoalquilo C1-6, (alquil C1-6)aminoalquilo C1-6, di(alquil C1-6)aminoalquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6 o (alcoxi C1-6)alquilo, en los que cada uno de los restos alcoxi y alquilo de los grupos R4 y R5 anteriores puede estar opcionalmente sustituido con uno a tres átomos de halo, preferiblemente con uno a tres átomos de fluor; R6, R7, R8 y R9, son, independientemente, hidrogeno o alquilo C1-6 opcionalmente sustituido con uno a tres átomos de fluor; Y, cuando R11 está presente, se selecciona de O, NR13, en el que R13 se define tal como se define R10 anteriormente o (CH2)w en el que w es un numero entero de uno o seis; o Y, cuando R11 está ausente, se selecciona de (=O), hidroxi, NR13R14 en el que R13 y R14 se definen tal como se define R10 anteriormente y (CH2)qCH3, en el que q es un numero entero de uno a cinco; n es un numero entero de uno a tres; z es un numero entero de uno a tres; y R11 es hidrogeno, -SO2-alquilo(C1-6), -SO2-arilo, arilo, arilalquilo C1-6, heteroarilo, heteroarilalquilo C1-6, heterociclilo, heterociclilalquilo C1-4, COR15, C(O)OR15 o C(O)NR15R16, en los que R15 y R16 se seleccionan independientemente de alquilo C1-6, arilo, heteroarilo, heteroarilalquilo C1-6, arilalquilo C1-6, heterociclilo y heterociclilalquilo C1-6; en los que dichos restos alquilo en dichos grupos R11 pueden estar opcionalmente sustituidos con uno a tres átomos de fluor y los restos arilo, heteroarilo y heterociclilo en dichos grupos R11 pueden estar opcionalmente sustituidos, con uno o más sustituyentes, preferiblemente de cero a dos sustituyentes, que se seleccionan independientemente de alquilo C1-6 opcionalmente sustituido con uno a tres átomos de fluor, alcoxi C1-6 opcionalmente sustituido con uno a tres átomos de fluor, ciano, nitro, halo, amino, (alquil C1-6)amino y di(alquil C1-6)amino; o R11 está ausente; con la condicion de que la suma de n más z no puede superar 3; y las sales farmacéuticamente aceptables de tales compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52785203P | 2003-12-08 | 2003-12-08 | |
| US53109603P | 2003-12-19 | 2003-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047325A1 true AR047325A1 (es) | 2006-01-18 |
Family
ID=34811295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104547A AR047325A1 (es) | 2003-12-08 | 2004-12-06 | Derivados de indano sustituidos y compuestos relacionados para el tratamiento de la esquizofrenia. composiciones farmaceuticas que los contienen. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050282819A1 (es) |
| EP (1) | EP1697334A1 (es) |
| JP (1) | JP2007513197A (es) |
| AR (1) | AR047325A1 (es) |
| BR (1) | BRPI0416739A (es) |
| CA (1) | CA2548447A1 (es) |
| NL (1) | NL1027680C2 (es) |
| PA (1) | PA8619301A1 (es) |
| PE (1) | PE20050862A1 (es) |
| TW (1) | TW200524922A (es) |
| UY (1) | UY28656A1 (es) |
| WO (1) | WO2005056540A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
| WO2007076601A1 (en) * | 2006-01-03 | 2007-07-12 | Clera Inc. | Imaging of d2high receptors using radiolabelled (-)- quinpirole and analogs thereof |
| TW200804347A (en) * | 2006-01-10 | 2008-01-16 | Janssen Pharmaceutica Nv | Urotensin II receptor antagonists |
| EP1999121A1 (en) * | 2006-03-17 | 2008-12-10 | AstraZeneca AB | Novel tetralins as 5-ht6 modulators |
| KR20090040352A (ko) | 2006-07-31 | 2009-04-23 | 얀센 파마슈티카 엔.브이. | 유로텐신 ⅱ 수용체 길항제 |
| WO2010017105A1 (en) * | 2008-08-02 | 2010-02-11 | Janssen Pharmaceutica N.V. | Urotensin ii receptor antagonists |
| TW201040153A (en) | 2009-02-13 | 2010-11-16 | Sanofi Aventis | Novel substituted tetrahydronaphthalenes, process for preparation thereof and use thereof as medicaments |
| AR075401A1 (es) * | 2009-02-13 | 2011-03-30 | Sanofi Aventis | Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento |
| CN104140421B (zh) * | 2013-05-08 | 2017-04-05 | 上海医药工业研究院 | 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
| FR2654104B1 (fr) * | 1989-11-07 | 1992-01-03 | Adir | Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2671350A1 (fr) * | 1991-01-08 | 1992-07-10 | Adir | Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant. |
| IL101722A (en) * | 1991-05-02 | 1996-05-14 | Wyeth John & Brother Ltd | Piperazine derivatives their preparation and pharmaceutical compositions containing them |
| US6242450B1 (en) * | 1998-07-27 | 2001-06-05 | Eli Lilly And Company | 5-HT1F antagonists |
| CN1164574C (zh) * | 1999-05-24 | 2004-09-01 | 三菱制药株式会社 | 苯氧基丙胺类化合物 |
| AU7547100A (en) * | 1999-09-09 | 2001-04-10 | Egis Gyogyszergyar Rt. | Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient |
| MXPA05002007A (es) * | 2002-09-17 | 2005-04-28 | Warner Lambert Co | Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia. |
| BR0314796A (pt) * | 2002-09-26 | 2005-07-26 | Warner Lambert Co | Piperazinas substituìdas heterocìclicas para o tratamento de esquizofrenia |
-
2004
- 2004-11-26 BR BRPI0416739-2A patent/BRPI0416739A/pt not_active IP Right Cessation
- 2004-11-26 WO PCT/IB2004/003898 patent/WO2005056540A1/en not_active Ceased
- 2004-11-26 CA CA002548447A patent/CA2548447A1/en not_active Abandoned
- 2004-11-26 JP JP2006543635A patent/JP2007513197A/ja active Pending
- 2004-11-26 EP EP04799000A patent/EP1697334A1/en not_active Withdrawn
- 2004-12-06 AR ARP040104547A patent/AR047325A1/es unknown
- 2004-12-06 UY UY28656A patent/UY28656A1/es not_active Application Discontinuation
- 2004-12-06 PE PE2004001197A patent/PE20050862A1/es not_active Application Discontinuation
- 2004-12-07 TW TW093137739A patent/TW200524922A/zh unknown
- 2004-12-07 NL NL1027680A patent/NL1027680C2/nl not_active IP Right Cessation
- 2004-12-07 PA PA20048619301A patent/PA8619301A1/es unknown
- 2004-12-08 US US11/007,486 patent/US20050282819A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200524922A (en) | 2005-08-01 |
| BRPI0416739A (pt) | 2007-01-16 |
| WO2005056540A1 (en) | 2005-06-23 |
| NL1027680A1 (nl) | 2005-06-09 |
| NL1027680C2 (nl) | 2005-11-30 |
| PE20050862A1 (es) | 2005-12-17 |
| JP2007513197A (ja) | 2007-05-24 |
| EP1697334A1 (en) | 2006-09-06 |
| UY28656A1 (es) | 2005-07-29 |
| CA2548447A1 (en) | 2005-06-23 |
| US20050282819A1 (en) | 2005-12-22 |
| PA8619301A1 (es) | 2005-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045180A1 (es) | Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos | |
| HRP20040977B1 (hr) | Derivati n-[fenil(piperidin-2-il)metil]benzamida,postupak njihovog pripravljanja i primjena istih u terapiji | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| AR035854A1 (es) | Compuestos derivados de piridopirimidina y naftiridina, su uso, un procedimiento para prepararlos, una composicion que los comprende, compuestos intermediarios y un proceso para preparar un compuesto sulfuro | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| PE20080689A1 (es) | Derivados de amina inhibidores de quinasa | |
| CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
| TW200738706A (en) | Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
| AR001787A1 (es) | Un compuesto oxazolidin sustituido particularmenteutil como inhibidor de calpaina y/o catepsina b e n el tratamiento de trastornos neurodegenerativos agudos o cronicos y composiciones farmacéuticas que incluyen dicho compuesto | |
| MEP12608A (en) | Derivatives of n-[phenyl (pyrrolidine-2-yl) methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | |
| AR065927A1 (es) | Derivados de 5,6-dihidro-1h-piridin-2-ona | |
| AR069961A1 (es) | Derivados de (aza)indol sustituidos en la posicion 5 utiles en el tratamiento de la inflamacion y el dolor, composiciones farmaceuticas que los comprenden, proceso de preparacion de los mismos y compuestos intermediarios. | |
| CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| AR047325A1 (es) | Derivados de indano sustituidos y compuestos relacionados para el tratamiento de la esquizofrenia. composiciones farmaceuticas que los contienen. | |
| AR063805A1 (es) | Derivados de triazol sustituidos como inhibidores de ksp. composiciones farmaceuticas. | |
| SE0201937D0 (sv) | Therapeutic agents | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| EA200500717A1 (ru) | Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат | |
| AR071514A1 (es) | Derivados de aminopiridina | |
| ECSP088257A (es) | Derivados de amida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |